IR@PKUHSC  > 北京大学第一临床医学院  > 血液内科
学科主题临床医学
High efficacy and good tolerability with rituximab in vivo purging followed by high dose chemotheraphy and autologous peripheral blood stem cell transplantation (APBSCT) in non-Hodgkin′s lymphoma (NHL).
Shi, YK; Yang, S; Han, XH; Liu, P; He, XH; Ma, J; Ren, HY; Cen, X; Zhou, SY; Wang, C
刊名BLOOD
2004-11-16
104期:11页:240B-240B
收录类别ISTP ; SCI
文章类型Meeting Abstract
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
语种英语
WOS记录号WOS:000225127700956
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61701
专题北京大学第一临床医学院_血液内科
作者单位1.Shanghai First Peoples Hosp, Dept Hematol, Shanghai, Peoples R China
2.Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp Inst, Beijing 100037, Peoples R China
3.Peking Union Med Coll, Beijing, Peoples R China
4.Haerbin Inst Hematopathy, Dept Hematol, Haerbin, Heilongjing, Peoples R China
5.Peking Univ, Dept Hematol, Hosp 1, Beijing 100871, Peoples R China
6.First Mil Med Univ, Dept Hematol, Nanfang Hosp, Guangzhou, Peoples R China
推荐引用方式
GB/T 7714
Shi, YK,Yang, S,Han, XH,et al. High efficacy and good tolerability with rituximab in vivo purging followed by high dose chemotheraphy and autologous peripheral blood stem cell transplantation (APBSCT) in non-Hodgkin′s lymphoma (NHL).[J]. BLOOD,2004,104(11):240B-240B.
APA Shi, YK.,Yang, S.,Han, XH.,Liu, P.,He, XH.,...&Wang, C.(2004).High efficacy and good tolerability with rituximab in vivo purging followed by high dose chemotheraphy and autologous peripheral blood stem cell transplantation (APBSCT) in non-Hodgkin′s lymphoma (NHL)..BLOOD,104(11),240B-240B.
MLA Shi, YK,et al."High efficacy and good tolerability with rituximab in vivo purging followed by high dose chemotheraphy and autologous peripheral blood stem cell transplantation (APBSCT) in non-Hodgkin′s lymphoma (NHL).".BLOOD 104.11(2004):240B-240B.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Shi, YK]的文章
[Yang, S]的文章
[Han, XH]的文章
百度学术
百度学术中相似的文章
[Shi, YK]的文章
[Yang, S]的文章
[Han, XH]的文章
必应学术
必应学术中相似的文章
[Shi, YK]的文章
[Yang, S]的文章
[Han, XH]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。